Secondary Logo

An Investigation into Variability in the Therapeutic Response to Deferiprone in Patients with Thalassemia Major

Retraction

Therapeutic Drug Monitoring: April 2019 - Volume 41 - Issue 2 - p 256
doi: 10.1097/FTD.0000000000000607
Erratum
Free

Received January 25, 2019

Accepted January 25, 2019

The article “An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major” by Diav-Citrin et al. has been retracted due to concerns regarding academic and research misconduct, including the use of collaborators’ data without their consent, and, as a consequence, inappropriate assignment of authorship. Moreover, the manufacturer of the studied drug was not appropriately identified as a funding source. This was corrected in an Erratum published in Therapeutic Drug Monitoring, Volume 26, Number 2, April 2004. However, none of the other issues were addressed. This retraction is supported by the results of an independent investigation conducted by the University of Toronto and a written retraction request by the senior author, who is listed as the last author.

Back to Top | Article Outline

REFERENCE

Diav-Citrin O, Atanackovic G, Koren G. An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major. Ther Drug Monit. 1999;21:74–81.
    Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.